{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.233","value":"0.038"}]}],"title":"Change in Index Score at Cycle 2 (n=43)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.147","value":"0.070"}]}],"title":"Change in Index Score at Cycle 4 (n=29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.249","value":"-0.063"}]}],"title":"Change in Index Score at Cycle 6 (n=24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.098","value":"0.016"}]}],"title":"Change in Index Score at monotherapy Cycle2 (n=14)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.080","value":"0.059"}]}],"title":"Change in Index Score at monotherapy Cycle 4 (n=7)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.600","value":"3.854"}]}],"title":"Change in VAS Score at Cycle 2 (n=41)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.894","value":"2.107"}]}],"title":"Change in VAS Score at Cycle 4 (n=28)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.716","value":"0.333"}]}],"title":"Change in VAS Score at Cycle 6 (n=21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.919","value":"-1.500"}]}],"title":"Change in VAS Score at monotherapy Cycle 2 (n=14)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.377","value":"0.571"}]}],"title":"Change in VAS Score at monotherapy Cycle 4 (n=7)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. The EQ-5D Visual Analog Scale (VAS) is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).","dispersionType":"Standard Deviation","groups":[{"description":"Cetuximab loading dose of 400 mg/m² administered intravenously on Day 1 of Cycle 1; subsequently 250 mg/m² administered intravenously weekly.\n\nPemetrexed 500 mg/m² administered intravenously on Day 1 of every 21-day cycle, 1 hour after cetuximab.\n\nCarboplatin AUC 5 or cisplatin 75 mg/m² administered intravenously on Day 1 of every 21-day cycle, 30 minutes after pemetrexed.\n\nMaximum 6 cycles. Participants who did not experience disease progression after 6 cycles continued on cetuximab (250 mg/m² intravenously weekly) monotherapy until disease progression.","id":"OG000","title":"Cetuximab + Pemetrexed + Carboplatin/Cisplatin"}],"paramType":"MEAN","populationDescription":"All treated participants who completed the EQ-5D-3L and VAS at baseline and in Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4. Exclude those from a noncompliant study site.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)","title":"Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)","type":"SECONDARY","unitOfMeasure":"units on a scale"}